Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001701541-25-000022
Filing Date
2025-05-12
Accepted
2025-05-12 16:08:45
Documents
70
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bdtx-20250331.htm   iXBRL 10-Q 785379
2 EX-10.1 bdtx-licenseagreement.htm EX-10.1 509514
3 EX-31.1 exhibit311_q12025.htm EX-31.1 12490
4 EX-31.2 exhibit312_q12025.htm EX-31.2 12335
5 EX-32.1 exhibit321_q12025.htm EX-32.1 9381
11 GRAPHIC image_0.jpg GRAPHIC 4978
12 GRAPHIC image_1.jpg GRAPHIC 38987
  Complete submission text file 0001701541-25-000022.txt   5488634

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bdtx-20250331.xsd EX-101.SCH 30248
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bdtx-20250331_cal.xml EX-101.CAL 51519
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bdtx-20250331_def.xml EX-101.DEF 122769
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bdtx-20250331_lab.xml EX-101.LAB 489693
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bdtx-20250331_pre.xml EX-101.PRE 325386
73 EXTRACTED XBRL INSTANCE DOCUMENT bdtx-20250331_htm.xml XML 585969
Mailing Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142 617-417-5868
Black Diamond Therapeutics, Inc. (Filer) CIK: 0001701541 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39200 | Film No.: 25934839
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)